| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
24021 |
| Drug |
Ciltacabtagene autoleucel |
| Brand |
Carvykti® |
| Indication |
For the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide. |
| Rapid review commissioned |
04/06/2024 |
| Rapid review completed |
08/07/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ciltacabtagene autoleucel for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/07/2024 |
| Pre-submission consultation with Applicant |
04/09/2024 |
